Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review ; volume:42 ; number:4 ; day:24 ; month:1 ; year:2024 ; pages:373-392 ; date:4.2024
PharmacoEconomics ; 42, Heft 4 (24.1.2024), 373-392, 4.2024
- Creator
-
Marquina, Clara
Morton, Jedidiah I.
Lloyd, Melanie
Abushanab, Dina
Baek, Yeji
Abebe, Tamrat
Livori, Adam
Dahal, Padam
Watts, Gerald
Ademi, Zanfina
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-023-01347-7
- URN
-
urn:nbn:de:101:1-2405152109046.419254814954
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Marquina, Clara
- Morton, Jedidiah I.
- Lloyd, Melanie
- Abushanab, Dina
- Baek, Yeji
- Abebe, Tamrat
- Livori, Adam
- Dahal, Padam
- Watts, Gerald
- Ademi, Zanfina
- SpringerLink (Online service)
Other Objects (12)
Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
Cost-effectiveness of osteoporosis screening and biases in cost-effectiveness analyses
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
The probability of cost-effectiveness
Cost-effectiveness analysis for clinicians
Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
Cost-Effectiveness of Targeted Reemployment Bonuses
Cost-effectiveness and algorithmic decision-making
Challenges in synthesising cost-effectiveness estimates
Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer
Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
Cost-effectiveness of osteoporosis screening and biases in cost-effectiveness analyses
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
The probability of cost-effectiveness
Cost-effectiveness analysis for clinicians
Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
Cost-Effectiveness of Targeted Reemployment Bonuses
Cost-effectiveness and algorithmic decision-making
Challenges in synthesising cost-effectiveness estimates
Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer
Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
Cost-effectiveness of osteoporosis screening and biases in cost-effectiveness analyses
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
The probability of cost-effectiveness
Cost-effectiveness analysis for clinicians
Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
Cost-Effectiveness of Targeted Reemployment Bonuses
Cost-effectiveness and algorithmic decision-making
Challenges in synthesising cost-effectiveness estimates
Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model